Vocal Acoustic Biomarkers of Depression Severity and Treatment Response
James C Mundt, Adam P Vogel, Douglas E Feltner, William R Lenderking
BIOLOGICAL PSYCHIATRY | ELSEVIER SCIENCE INC | Published : 2012
Related Projects (1)
Awarded by National Institute of Mental Health Small Business Innovation Research Grant
Awarded by National Health and Medical Research Council (Australia)
Awarded by NATIONAL INSTITUTE OF MENTAL HEALTH
Funding support was provided by Pfizer, Inc. and through National Institute of Mental Health Small Business Innovation Research Grant National Institute of Mental Health (R44 MH068950).Dr. Mundt has received research support grants from Glaxo SmithKline, Pfizer, Eli Lilly, Eisai, the National Institutes of Health, and the US Department of Agriculture. Dr. Mundt provides consulting services to ERT, a company that provides services to the pharmaceutical industry. Dr. Mundt is a former employee of and owns stock in Healthcare Technology Systems, a research and development company that develops computer-automated patient assessment programs. Dr. Vogel has received research support from the National Health and Medical Research Council (Australia, #10012302) and is a former employee of CogState Ltd, a company that provides services to the pharmaceutical industry, and owns CogState stock. Dr. Feltner is Chief Medical Officer for and has stock options in Embera Neurotherapeutics, a company focused on smoking cessation and other drug abuse treatments. Dr. Feltner is a former employee of Pfizer Inc. and owns Pfizer stock. Dr. Lenderking was the Principal Investigator of this study and was a full-time employee of Pfizer, the manufacturer of sertraline, during the time this study was conceived and implemented. He continues to be a Pfizer stockholder. He is currently an employee of United BioSource Corporation, a wholly owned subsidiary of Express Scripts, Inc,. United BioSource Corporation is a company that provides consulting services for hire to the pharmaceutical, biotech, and device industries.